Skip to main content

Table 2 Baseline Demographics and Characteristics

From: A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

 

ABC/3TC/ZDV (N = 139)

ATV+3TC/ZDV (N = 140)

Median Age, years (range)

38 (19–65)

36 (18–68)

Female Gender, n (%)

30 (22%)

28 (20%)

Race, n (%)

  

   White

65 (47%)

58 (41%)

   Black

44 (32%)

49 (35%)

   American Hispanic

26 (19%)

29 (21%)

   Other

4 (3%)

4 (3%)

CDC Class C, n (%)

6 (4%)

5 (4%)

Median HIV-1 RNA, log10 copies/mL (range)

4.48 (2.3–5.5)

4.64 (2.6–5.6)

HIV-1 RNA ≥ 100,000 copies/mL, n (%)

24 (17%)

25 (18%)

Median CD4+ cell count, (cells/mm3) (range)

274 (103–889)

262 (50–749)

CD4+ cell count ≥ 200 cells/mm3, n (%)

105 (76%)

97 (69%)

Hepatitis B positive, n (%)

2 (1%)

6 (4%)

Hepatitis C positive, n (%)

9 (6%)

10 (7%)

Hepatitis & B positive, n (%)

0

1 (<1%)

  1. Abbreviations: abacavir sulfate (ABC), atazanavir (ATV), lamivudine (3TC), zidovudine (ZDV)